echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Circulation: The Changxing team of West Lake University uses base editing to bring hope to cure Duchenne muscular dystrophy

    Circulation: The Changxing team of West Lake University uses base editing to bring hope to cure Duchenne muscular dystrophy

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Duchenne muscular dystrophy (DMD) is a single-gene genetic disease.


    As one of the most common fatal genetic diseases, it is estimated that one DMD patient will occur in every 3500-5000 newborn males


    In recent years, the rapid development of gene editing technology has brought new hope for the treatment of single-gene genetic diseases such as DMD


    Recently, Life Sciences, University of the West Lake Chang Xing research group in Circulation published online entitled: Therapeutic Exon Skipping Via A CRISPR-Guided Cytidine Deaminase rescues dystrophic an In Vivo Cardiomyopathy research papers


    Circulation Circulation Therapeutic Exon Skipping via a CRISPR-guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy In Vivo Therapeutic Exon Skipping via a CRISPR-guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy In Vivo

    This study proved that the use of CRISPR-AID (TAM) base editor can efficiently induce exon skipping in mouse models, restore Dystrophin protein expression, and cure Duchenne muscular dystrophy


    Researcher Chang Xing of West Lake University is the corresponding author of this article, and assistant researcher Dr.


    Previously, Chang Xing's research group independently developed the CRISPR-AID (TAM) base editor (Nature Methods-2016), and based on this, created a genetic manipulation system for RNA splicing (Molecular Cell-2018)


    In order to explore the therapeutic effect of this gene editing system on DMD, the research team first identified a new mouse model---DmdE4*


    Figure 1 Principle of gene therapy (A) and treatment plan (B) for DmdE4* mice

    Figure 1 Principle of gene therapy (A) and treatment plan (B) for DmdE4* mice Figure 1 Principle (A) and treatment plan (B) of gene therapy for DmdE4* mice

    In response to this model, the research team targeted the exons carrying disease-causing mutations and used the Cas9-AID base editor to induce a G>A mutation at the 5'splice site of the target exon to make it an exon.


    Figure 2 For the gene therapy effect of DmdE4* mice, A.


    Figure 2 For the gene therapy effect of DmdE4* mice, A.


    At the same time, the Changxing team’s research results have completed the initial transformation of results, and cooperated with emerging domestic gene therapy companies to strive to overcome genetic diseases that are difficult to cure by traditional methods such as DMD as soon as possible


    Original source:

    Original source:

    Jia Li, Kaiying Wang, Yuchen Zhang, et al.


    Therapeutic Exon Skipping via a CRISPR-guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy In Vivo

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.